Literature DB >> 30641484

Hepatitis B Virus Infection: What Is Current and New.

Marion G Peters1.   

Abstract

Hepatitis B virus (HBV) infection is a lifelong dynamic disease that can be controlled with treatment but cannot yet be cured. Risk of end-stage liver disease and hepatocellular carcinoma (HCC) increases with ongoing inflammation and HBV viremia. Initial treatments consist of tenofovir or entecavir. Patients who require treatment include those with chronic hepatitis, cirrhosis, HCC, or HIV coinfection; patients receiving immunosuppressive treatments; and women in the third trimester of pregnancy who have elevated HBV DNA level. A number of virologic and host immune approaches are being investigated with the aim of achieving HBV eradication. This article summarizes an IAS-USA webinar given by Marion G. Peters, MD, on June 14, 2018.

Entities:  

Mesh:

Year:  2019        PMID: 30641484      PMCID: PMC6372357     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN: 2161-5853


  4 in total

1.  Adherence and Effectiveness of HBV Vaccination among Healthcare Workers in Egypt.

Authors:  Mohammed Elshaer; Eman Elsayed; Abdel-Hady El-Gilany; Noha El-Mashad; Mostafa Mansour
Journal:  Indian J Occup Environ Med       Date:  2021-07-09

Review 2.  Multifaceted Functions of Host Cell Caveolae/Caveolin-1 in Virus Infections.

Authors:  Yifan Xing; Zeyu Wen; Wei Gao; Zhekai Lin; Jin Zhong; Yaming Jiu
Journal:  Viruses       Date:  2020-04-26       Impact factor: 5.048

3.  Liver damage favors the eliminations of HBV integration and clonal hepatocytes in chronic hepatitis B.

Authors:  Gang Hu; Ming X Huang; Wei Y Li; Chong J Gan; Wen X Dong; Xiao M Peng
Journal:  Hepatol Int       Date:  2021-02-03       Impact factor: 6.047

4.  Notoamide-type alkaloid induced apoptosis and autophagy via a P38/JNK signaling pathway in hepatocellular carcinoma cells.

Authors:  Likun Hu; Ting Zhang; Dong Liu; Guiwen Guan; Jian Huang; Peter Proksch; Xiangmei Chen; Wenhan Lin
Journal:  RSC Adv       Date:  2019-06-25       Impact factor: 4.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.